Platelet-rich Plasma as an Adjuvant Therapy to Crystallized Phenol in the Treatment of Pediatric Pilonidal Sinus Disease: A Prospective Randomized Controlled Trial

Basit Öğe Kaydı
dc.authorscopusidMustafa Azizoğlu / 58901683600
dc.authorwosidMustafa Azizoğlu / HKV-3601-2023
dc.contributor.authorAzizoğlu, Mustafa
dc.contributor.authorKlyuev, Sergey
dc.contributor.authorKamçı, Tahsin Onat
dc.contributor.authorOkur, Mehmet Hanifi
dc.date.accessioned2025-04-18T10:11:47Z
dc.date.available2025-04-18T10:11:47Z
dc.date.issued2025
dc.departmentİstinye Üniversitesi, Lisansüstü Eğitim Enstitüsü, Sağlık Bilimleri, Kök Hücre ve Doku Mühendisliği Programı
dc.description.abstractObjective: This study aims to evaluate the safety and efficacy of platelet-rich plasma (PRP) as an adjuvant to crystallized phenol (CP) in treating pediatric pilonidal sinus disease (PSD). Methods: A single-center randomized controlled trial was conducted at Istanbul Esenyurt Hospital. Eighty-seven patients aged 0–18 were randomly assigned to two groups: the CP group (n = 42) and the CP + PRP group (n = 45). Upon arrival at the clinic, patients began a regimen of manual shaving and, if necessary, laser epilation every 6–8 weeks. For those with pilonidal abscesses, incision, drainage, and antibiotics were given. The treatment area was sterilized and numbed with local anesthesia. Hair removal and curettage were performed, followed by the application of crystallized phenol. In CP + PRP group, PRP injections were also administered. The procedure concluded with wound dressing and thorough disinfection. The study was registered https://clinicaltrials.gov/ (NCT06324656). Results: The CP + PRP group demonstrated significantly shorter healing times (19.4 ± 7.88 days) compared to the CP group (30.7 ± 12.9 days) (p < 0.001). The cosmetic score was higher in the CP + PRP group (7.42 ± 1.61) than in the CP group (6.11 ± 1.88, p = 0.001). CP + PRP group had lower VAS scores at measured all-time points after applications (p < 0.05 for each). Complications were comparable between the groups, with no significant differences in bleeding, infections, or skin burns (p > 0.05 for each comparison). No difference was found between groups in terms of total complication rate (p = 0.398). The success rate was higher in CP + PRP group (98%; n = 44) compared to CP group (86%; n = 36) (p = 0.039). Recurrence rates were lower in CP + PRP group (2%; n = 1) than CP group (14%; n = 6) (p = 0.039). Conclusion: The autologous PRP injection in pediatric PSD is safe. The addition of PRP to CP treatment for pediatric PSD significantly improves healing time, cosmetic outcomes, and overall success rates without increasing complication rates. This combined approach offers a promising alternative for effective and efficient treatment of PSD in children. Type of the study: Randomized controlled trial. Level of evidence: Level I © 2024 Elsevier Inc.
dc.identifier.citationAzizoglu, M., Klyuev, S., Kamci, T. O., & Okur, M. H. (2025). Platelet-rich Plasma as an Adjuvant Therapy to Crystallized Phenol in the Treatment of Pediatric Pilonidal Sinus Disease: A Prospective Randomized Controlled Trial. Journal of Pediatric Surgery, 60(1), 161934.
dc.identifier.doi10.1016/j.jpedsurg.2024.161934
dc.identifier.issn00223468
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85204409253
dc.identifier.scopusqualityQ1
dc.identifier.urihttp://dx.doi.org/10.1016/j.jpedsurg.2024.161934
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6987
dc.identifier.volume60
dc.indekslendigikaynakScopus
dc.institutionauthorAzizoğlu, Mustafa
dc.institutionauthoridMustafa Azizoğlu / 0009-0000-3563-1230
dc.language.isoen
dc.publisherW.B. Saunders
dc.relation.ispartofJournal of Pediatric Surgery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCrystallized Phenol
dc.subjectPediatric Pilonidal Sinus Disease
dc.subjectPlatelet-Rich Plasma
dc.titlePlatelet-rich Plasma as an Adjuvant Therapy to Crystallized Phenol in the Treatment of Pediatric Pilonidal Sinus Disease: A Prospective Randomized Controlled Trial
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1-s2.0-S0022346824008431-main.pdf
Boyut:
2.07 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Kök Hücre ve Doku Mühendisliği Programı Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu